Market Indices
Sector Heatmap
EPRX — Eupraxia Pharmaceuticals Inc. Common Stock
NasdaqEupraxia Pharmaceuticals Inc. Common Stock
- O
- 8.00
- H
- 8.09
- L
- 7.19
- V
- 1.71M
EPRX — Latest News & Headlines
20 StoriesFifty-two weeks after one dose, 9 of 14 patients with an esophageal disease remained in remission. - stocktitan.net
Fifty-two weeks after one dose, 9 of 14 patients with an esophageal disease remained in remission. stocktitan.net
Eupraxia Pharmaceuticals (TSX:EPRX) Stock Drops 13.86% After 52-Week RESOLVE Data as Phase 2b Readout Moves to December - kalkine.ca
Eupraxia Pharmaceuticals (TSX:EPRX) Stock Drops 13.86% After 52-Week RESOLVE Data as Phase 2b Readout Moves to December kalkine.ca
(EPRX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
(EPRX) Movement Within Algorithmic Entry Frameworks Stock Traders Daily
Stifel reiterates Buy rating on Eupraxia stock ahead of trial data - Investing.com
Stifel reiterates Buy rating on Eupraxia stock ahead of trial data Investing.com
After one dose, Eupraxia (EPRX) reports patients still in remission at 52 weeks. - stocktitan.net
After one dose, Eupraxia (EPRX) reports patients still in remission at 52 weeks. stocktitan.net
Stock Market sell-off: These eight Nifty 50 stocks are at or near 52-week lows - CNBC TV18 - LinkedIn
Stock Market sell-off: These eight Nifty 50 stocks are at or near 52-week lows - CNBC TV18 LinkedIn
Eupraxia Says Resolve Trial Updated Data Suggest Annual Dosing Possible in EoE Patients - marketscreener.com
Eupraxia Says Resolve Trial Updated Data Suggest Annual Dosing Possible in EoE Patients marketscreener.com
Wedbush initiates Eupraxia Pharmaceuticals stock with Outperform rating - Investing.com
Wedbush initiates Eupraxia Pharmaceuticals stock with Outperform rating Investing.com
Eupraxia Pharmaceuticals (TSX:EPRX) Stock Slips 5.13%: RESOLVE Trial Execution, Diffusphere Formulation Pacing, and Pre-Commercial Valuation Scrutinized - kalkine.ca
Eupraxia Pharmaceuticals (TSX:EPRX) Stock Slips 5.13%: RESOLVE Trial Execution, Diffusphere Formulation Pacing, and Pre-Commercial Valuation Scrutinized kalkine.ca
Wainwright reiterates Eupraxia stock rating on positive trial data By Investing.com - Investing.com Nigeria
Wainwright reiterates Eupraxia stock rating on positive trial data By Investing.com Investing.com Nigeria
Eupraxia Pharmaceuticals (TSX:EPRX) Gains Momentum as Durable EoE Data Strengthens Investor Optimism - kalkine.ca
Eupraxia Pharmaceuticals (TSX:EPRX) Gains Momentum as Durable EoE Data Strengthens Investor Optimism kalkine.ca
Custom Health Holdings (TSX:CHLT) Stock Drops 5.45%: Spencer Health Integration Pacing, Convertible Debt Overhang, and Digital Pharmacy Margins Scrutinized - kalkine.ca
Custom Health Holdings (TSX:CHLT) Stock Drops 5.45%: Spencer Health Integration Pacing, Convertible Debt Overhang, and Digital Pharmacy Margins Scrutinized kalkine.ca
Why Is COSCIENS Biopharma Stock Down 5.41%? Key Drivers and What Investors Are Watching (TSX:CSCI) - kalkine.ca
Why Is COSCIENS Biopharma Stock Down 5.41%? Key Drivers and What Investors Are Watching (TSX:CSCI) kalkine.ca
Jushi Holdings Stock Rebounds 13.89% After Rescheduling Hearing Stay Triggered Sharp Pullback (CN:JUSH) - kalkine.ca
Jushi Holdings Stock Rebounds 13.89% After Rescheduling Hearing Stay Triggered Sharp Pullback (CN:JUSH) kalkine.ca
Covalon Technologies Stock Rises 8.68% to New Highs as Record Quarter and AVA Showcase Lift Sentiment (TSXV:COV) - kalkine.ca
Covalon Technologies Stock Rises 8.68% to New Highs as Record Quarter and AVA Showcase Lift Sentiment (TSXV:COV) kalkine.ca
Cardiol Therapeutics Inc. Class A (TSX:CRDL) Slides -5.91% as Investors Reassess Near-Term Catalysts and Risk - kalkine.ca
Cardiol Therapeutics Inc. Class A (TSX:CRDL) Slides -5.91% as Investors Reassess Near-Term Catalysts and Risk kalkine.ca
Arch Biopartners, Inc. (TSXV:ARCH) Slides -6.74% as Investors Reassess Near-Term Catalysts and Risk - kalkine.ca
Arch Biopartners, Inc. (TSXV:ARCH) Slides -6.74% as Investors Reassess Near-Term Catalysts and Risk kalkine.ca
Devonian Health Group (TSXV:GSD) Stock Falls 8.38% as Investors Track NYSE American Listing Plan - kalkine.ca
Devonian Health Group (TSXV:GSD) Stock Falls 8.38% as Investors Track NYSE American Listing Plan kalkine.ca
HLS Therapeutics (TSX:HLS) Stock Falls 7.38% Despite Expanded Share Buyback - kalkine.ca
HLS Therapeutics (TSX:HLS) Stock Falls 7.38% Despite Expanded Share Buyback kalkine.ca
Decibel Cannabis Company Inc. (TSXV:DB) Jumps 3.05%: Why Investors Are Watching This Stock After the 1 October 2026 Move - kalkine.ca
Decibel Cannabis Company Inc. (TSXV:DB) Jumps 3.05%: Why Investors Are Watching This Stock After the 1 October 2026 Move kalkine.ca